Insider purchase and ownership details
Thomas J. Fallon, a director at Hercules Capital, Inc. (NASDAQ:HTGC), purchased 10,000 shares of the company’s common stock at $14.98 per share, a transaction valued at $149,800, according to a Form 4 filed with the Securities and Exchange Commission. The filing indicates the transaction took place on February 24, 2026. Following that purchase Fallon directly holds 5,779 shares and indirectly holds 130,369 shares through the Fallon Family Revocable Trust. The Form 4 was signed on Fallon’s behalf by Attorney-in-Fact Kiersten Zaza Botelho.
Share price context and dividend
The timing of Fallon's purchase coincides with the stock trading near its 52-week low of $14.96, with shares quoted at $15.12, according to InvestingPro data. Hercules Capital currently offers a dividend yield of 12.88%, as noted in public materials referenced in the filing.
Preliminary NAV and quarter-over-quarter change
Separately, Hercules Capital provided preliminary estimates for its fourth-quarter and year-end results, indicating a net asset value (NAV) per share between $12.10 and $12.16 as of December 31, 2025. The company characterized this range as an increase of $0.05 to $0.11 per share compared with the prior quarter.
Loan amendment with Savara
Hercules also amended a loan agreement with Savara, under which Savara may access up to an additional $75 million in funding, contingent on FDA approval of Savara’s investigational therapy, MOLBREEVI. That amended arrangement is described as part of Savara’s plan to secure roughly $150 million in non-dilutive capital for potential drug launch activities.
Analyst action and sector exposure concerns
In other developments, Piper Sandler lowered its rating on Hercules Capital from Overweight to Neutral. The firm cited concern over Hercules Capital’s 35% exposure to the software sector and the attendant potential disruption risks related to AI. Piper Sandler also reduced its price target for the company to $17.50 from $20.50.
Research access note
The filing and related market context reference InvestingPro, noting that InvestingPro subscribers can access a comprehensive Pro Research Report for additional analysis of HTGC’s insider activity and investment profile.
Summary
Hercules Capital director Thomas J. Fallon bought 10,000 shares for $149,800 on February 24, 2026, while the stock trades near its 52-week low. The company reported a modest NAV increase for the quarter, amended a loan to provide contingent funding to Savara, and was downgraded by Piper Sandler due to concentrated exposure to the software sector.
Key points
- Director Thomas J. Fallon purchased 10,000 shares at $14.98 each, totaling $149,800; he holds 5,779 shares directly and 130,369 indirectly via a family trust.
- Hercules reported preliminary NAV per share of $12.10 to $12.16 as of December 31, 2025, a quarter-over-quarter increase of $0.05 to $0.11.
- The company amended a loan with Savara allowing up to $75 million in additional contingent funding tied to FDA approval of MOLBREEVI; Piper Sandler downgraded HTGC citing 35% software exposure and reduced its price target to $17.50.
Risks and uncertainties
- Contingent funding: The additional $75 million available to Savara is subject to FDA approval of MOLBREEVI, introducing regulatory execution risk for that portion of the financing - impacting the healthcare and biotech financing pipeline.
- Sector concentration: Piper Sandler flagged Hercules Capital’s 35% exposure to the software sector and potential AI-related disruption risks, which could influence performance across the company’s tech-focused credit portfolio.
- Market valuation pressure: The stock is trading near its 52-week low, which may reflect broader market sentiment or company-specific valuation concerns and affects investor return expectations in the financials and lending sectors.
Additional details
The Form 4 disclosing Fallon's purchase was signed by Kiersten Zaza Botelho as Attorney-in-Fact. Investors seeking deeper proprietary analysis may refer to InvestingPro materials, which are cited as offering a Pro Research Report on HTGC’s insider activity and investment potential.